Last Updated: November 16, 2026

Napo Pharms Inc Company Profile

« Back to Dashboard


What is the competitive landscape for NAPO PHARMS INC

NAPO PHARMS INC has one approved drug.

There are two US patents protecting NAPO PHARMS INC drugs.

Summary for Napo Pharms Inc
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Napo Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes 8,962,680 ⤷  Start Trial ⤷  Start Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes 9,585,868 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Napo Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 7,323,195 ⤷  Start Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 8,574,634 ⤷  Start Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 7,341,744 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Last updated: July 30, 2026

Napo Pharms Inc Competitive Landscape Analysis: Market Position, Patent Strength, and Strategic Options

Napo Pharms Inc’s competitive landscape turns on whether it can convert its pipeline into regulatory approvals and durable IP that blocks generic and biosimilar entry. A complete, defensible assessment of market position, patent estate strength, FDA status, and litigation-driven risk depends on identifying the firm’s specific approved products and pipeline assets, then mapping each asset to (i) FDA exclusivities, (ii) Orange Book listings for small molecules, (iii) 351(a)/BLA exclusivities for biologics, and (iv) active Paragraph IV and patent-infringement cases. Without asset-level identification, any market share, revenue exposure, and patent strength conclusions would be incomplete.

What is Napo Pharms Inc’s market position and revenue exposure by product?

No product-level detail is provided. A credible market-position analysis requires naming (1) marketed drug(s), (2) indication(s), (3) dosage form(s), and (4) whether the company’s role is manufacturer, distributor, or licensee. Without those inputs, market sizing, customer concentration, and payer-channel leverage cannot be mapped.

Which therapeutic areas does Napo Pharms Inc compete in?

Not specified. Competitive positioning is indication-driven, including competitor set, clinical differentiation, reimbursement dynamics, and pathway-specific regulatory exposure.

Is Napo Pharms Inc competing with brands, generics, or biosimilars?

Not specified. Without knowing whether Napo’s assets are small molecules, biologics, or generics/authorized generics, the competitor set and entry risks differ materially.


What patents protect Napo Pharms Inc products, and how many are in-force?

Not specified. Patent protection must be anchored to named products and active ingredients, then enumerated by jurisdiction and claims category (compound, formulation, polymorph, method-of-use, device/delivery, manufacturing).

How strong is the patent estate for Napo Pharms Inc drugs?

Not specified. Patent strength is a function of:

  • claim breadth vs. enforceability,
  • expiry profile (compound vs. formulation vs. process),
  • prosecution quality and continuations,
  • litigation history and PTO outcomes,
  • FDA exclusivity overlap (market exclusivity, 3/5/7 years, pediatric, orphan, CRT).

Where is patent coverage geographically enforceable?

Not specified. A defensible answer needs jurisdiction list: US, EP, UK, JP, CN, IN, CA, AU, KR, and any PCT national phases. Without asset identification, geographic coverage cannot be constructed.


When does Napo Pharms Inc lose exclusivity and patent protection?

Not specified. Exclusivity and patent expiry require:

  • Orange Book active ingredient mapping (for NDA ANDA systems),
  • BLA/351(a) exclusivity determination (for biologics),
  • patent-by-patent expiration dates and relevant term adjustments,
  • any terminal disclaimers,
  • lifecycle events (new formulations, line extensions).

What generic entry risks exist for Napo Pharms Inc’s lead drugs (Paragraph IV, 505(b)(2), and 351(k))?

Not specified. Entry risk differs by:

  • whether the listed patents are blocking vs. non-blocking,
  • whether there are multiple independent blocking patents,
  • whether the asset is small molecule (ANDA, Paragraph IV) or biologic (Biosimilar, 351(k)),
  • whether Napo is the reference product holder or a licensee with enforceable rights.

Which companies are challenging Napo Pharms Inc patents?

Not specified. Challengers are identified through court dockets and FDA 30-month stay events tied to ANDA Paragraph IV filings or biosimilar reference product litigation.

What settlement agreements reduce litigation uncertainty?

Not specified. Settlement terms (scope, launch dates, carve-outs, license conditions) are needed to translate legal posture into actual launch risk.


What is the Orange Book status of Napo Pharms Inc products?

Not specified. Orange Book status is product- and applicant-specific:

  • listing status (patent-in-force vs. expired),
  • dosage-form and active-ingredient mapping,
  • expiration dates,
  • exclusivity codes and periods.

Without the product list, Orange Book completeness and timing cannot be determined.


What formulations are protected by Napo Pharms Inc patents (CRYSTAL FORMS, polymorphs, salts, and delivery systems)?

Not specified. Formulation barriers are one of the main ways to extend exclusivity beyond compound claims, but require:

  • identified active ingredient and proposed generic equivalence targets,
  • patent claim categories (polymorph, salt form, amorphous form, particle size, coating),
  • device/delivery patents for injectables, inhalation, transdermals, and combination products.

How do Napo Pharms Inc’s assets compare with competing drugs in the same indications?

Not specified. Comparative analysis must include:

  • mechanism-of-action,
  • clinical endpoint differences,
  • safety profile,
  • time-to-response,
  • dosing convenience,
  • current formulary positioning and access status,
  • price and contracting dynamics.

What FDA pathway status does Napo Pharms Inc have for its pipeline (NDA, 505(b)(2), ANDA, BLA, 351(k))?

Not specified. FDA pathway status determines:

  • regulatory timelines and change-control risk,
  • exclusivity availability,
  • generics/biosimilars likelihood to pursue 505(b)(2) or 351(k),
  • labeling scope and method-of-use infringement exposure.

What patent litigation affects Napo Pharms Inc (case list, outcomes, and injunction risk)?

Not specified. Litigation analysis depends on:

  • case captions and docket numbers,
  • asserted patents and claim construction outcomes,
  • procedural posture (early dismissal, Markman, discovery, trial),
  • stay status under 30-month framework (small molecules),
  • settlement vs. adjudication paths.

What is Napo Pharms Inc’s competitive strategy: licensing, partnerships, or in-house development?

Not specified. Competitive strategy materially impacts asset control:

  • license agreements (territory, sublicensing, prosecution control, enforcement rights),
  • co-development and commercialization terms,
  • milestones and royalty structures,
  • revert rights that affect who can enforce IP against generics/biosimilars.

How many patents cover Napo Pharms Inc’s lead active ingredients and dosage forms?

Not specified. Patent counts require specific identification of:

  • active ingredients,
  • NDA/BLA application identifiers,
  • Orange Book/National phase family lists,
  • in-force status determination.

Key Takeaways

  • A product-anchored framework is required to assess Napo Pharms Inc’s market position, patent strength, exclusivity timing, generic and biosimilar risks, and litigation-driven launch constraints.
  • Without named Napo Pharms Inc assets (approved products and pipeline programs), any detailed competitive landscape would be non-actionable for licensing, R&D prioritization, or litigation planning.

FAQs

  1. How can a generic competitor assess Napo Pharms Inc’s launch risk without the Orange Book listing details?
  2. What evidence most strongly predicts enforceable patent coverage for a new formulation lifecycle asset?
  3. How do method-of-use patents change infringement risk for 505(b)(2) or biosimilar labeling?
  4. What settlement structures typically shift effective launch dates in Paragraph IV cases?
  5. How should exclusivity timelines be modeled across pediatric, orphan, and pediatric clawback triggers?

References

  1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
  2. FDA. Drug Development and Drug Interactions: Orange Book and FDA exclusivity resources. U.S. Food and Drug Administration.
  3. FDA. Guidance for Industry: 35(a) and 351(k) pathways and biosimilar regulatory framework. U.S. Food and Drug Administration.
  4. FDA. Paragraph IV ANDA dispute framework and 30-month stay overview. U.S. Food and Drug Administration.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.